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ABSTRACT 
Background: The medical treatments for prostate cancer result in multiple impairments in body 
structure and declines functional abilities resulting in activity limitations and participation 
restrictions. Measurement of functional mobility is an essential outcome measure in survivorship 
care. 
Purpose: The purpose of this systematic review is to make recommendations of the best 
measurement tools to assess functional mobility in men treated for prostate cancer based on 
psychometric properties and clinical utility. 
Methods: Multiple electronic databases were searched from February to March, 2014. Studies of 
tools used to assess functional mobility were included if they met the following criteria: reported 
psychometric properties, were clinically feasible methods, and were published in the English 
language. Each outcome measure was reviewed independently and rated by two reviewers 
separately. A single Cancer EDGE Task Force Outcome Measure Rating Form was completed 
for each measure of functional mobility, and a recommendation was made using the 4-point 
Cancer EDGE Task Force Rating Scale.   
Results: Of the original 38,373 articles found, 152 were included in this review.  
Conclusions: Seven tests are highly recommended by the Oncology EDGE Task Force: 2- 
Minute Walk Test and  6-Minute Walk Test, 10-Meter Timed Walk, the Timed-Up and Go 
(TUG), 5 times sit to stand, the Short Performance Physical Battery, and the Physical 
Performance Battery for Patients with Cancer, based on good clinical utility and psychometric 
properties. 
Key words: Psychometrics, outcome measures, prostate neoplasms, functional mobility 
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INTRODUCTION 
 
Prostate cancer (PC) is the most common cancer in men in the United States, and the second 
leading cause of cancer death among males.1  The American Cancer Society (ACS) estimates 
that approximately 181,000 new cases of PC will be diagnosed in 2016, with mortality at less 
than 27,000.2 This means approximately 1 in 7 men will be diagnosed with PC during their 
lifetime, and most are living many years after the diagnosis. The relative 5-year survival rate in 
the United States is almost 100% for all stages of PC, while the 10-year and 15-year survival 
rates are 99% and 94%; respectively.3  According to ACS, more than 2.9 million men in the 
United States diagnosed with PC are still living as of January of 2016.2  
As the number of men surviving prostate cancer (PCS) continues to grow, research has 
demonstrated that many PCS will have significant impairments of body structures and function.3 
These impairments often go undetected and/or untreated, and consequently may result in frailty.3 
Men treated for prostate cancer will experience a decrease in lean muscle mass and strength 
during the first year of androgen deprivation therapy (ADT) with an estimated 50% of PCS 
receiving this treatment in the early stages.4  A typical course of ADT treatment may last 
anywhere from 2-3 years. During the first year of ADT, PCS will experience a deficiency in sex 
hormones, insulin resistance, increased central/visceral adiposity, decreased bone density, 
decreased lean muscle mass and whole body muscle strength.4 Adverse changes in muscle 
composition may exacerbate normal sarcopenia, further reducing muscular strength and 
endurance as well as functional mobility and independence.5  A study of older PCS (mean age 69 
years) found that these men are at a greater risk for other comorbid conditions and physical 
limitations (for example, cardiovascular disease, diabetes, osteoporosis, skeletal fractures, 
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impaired balance and falls) that may dramatically affect their muscle performance and physical 
function.6  
Evidence of the impact of ADT and cancer treatments on PCS is consistently strong in 
terms of a detrimental effect on functional abilities.  In a recent study of PCS post-treatment, 
24% had impairments in activities of daily living (ADLs), 42% had impairment in instrumental 
activities of daily living (IADLs), 56% had abnormal Short Physical Performance Battery 
(SPPB) findings, and 22% reported falls within the previous three months.4 Within the SPPB, 
deficits occurred within all subcomponents (balance, walking, and chair stands). Using a 
univariate analysis, age, deficits in ADLs and IADLs, and abnormal cognitive and functional 
screen findings were associated with an increased risk of decreased physical performance for 
PCS.6 When compared to age-matched healthy controls, survivors had a slower walking speed, 
poorer physical performance and lower levels of patient-reported physical function. Decreased 
gait speed is associated with mobility limitations, disability, and increased mortality. Deficits in 
ADLs, the use of an assistive device, and abnormal functional screening findings were associated 
with an increased risk of falling.6 Falls may lead to more serious injuries such as an increased 
risk of fractures and hospitalizations, thereby decreasing the quality of life and level of 
independence for survivors. In summary, the multitude of physiological changes resulting from 
ADT treatment of prostate cancer profoundly impacts the functional mobility of these men.  It is 
therefore essential to measure functional mobility in order to identify deficits, risks for further 
injury such as falls, and design and assess the effectiveness of appropriate treatment regimens. 
In 1991, the Task Force on Standards for Measurement in Physical Therapy of the 
American Physical Therapy Association (APTA) established the criteria for valid, reliable, 
objective, and standardized tests and measures to assist clinicians in providing the highest quality 
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of care.7  The assessment of appropriate outcome measures needs to consider the following 
elements: 1) which domain within the International Classification of Functioning, Disability, and 
Health (ICF) that the test measures; 2) the purpose of the measure relevant to obtaining 
discriminative, predictive, or evaluative information; 3) whether the measure is disease specific 
or more generic, and whether it is a self-report vs. performance-based measure; 4) the patient’s 
ability and goals, and the clinic’s requirements; 5) the psychometric properties, particularly 
reliability, validity, diagnostic accuracy, minimal detectable change, and minimal clinical 
important difference; and 6) the feasibility, including the time, equipment, cost, space and 
training required to administer and score the test results, overall burden on the patient to 
complete  the test, and consideration of culture and language barriers.8  The use of standardized 
outcome measures is an essential component of evidence-based practice and enhances 
communication with patients and payers.9 The leading barriers to a standardization of physical 
therapy outcome measures are primarily the lack of knowledge of the psychometric strength of 
measures as well as the clinical utility of these measures including the length of time and level of 
difficulty for patients to complete the test as well as the time necessary for clinicians to 
administer and interpret the results of the tests.10 The Evaluation Database to Guide 
Effectiveness (EDGE) Task Force was developed to address these barriers in the physical 
therapy profession. 
In 2010, the APTA’s Oncology Section created an EDGE Task Force to develop 
recommendations for outcome measures used when assessing the status of cancer survivors.11 
The reliability, validity, minimal detectable change (MDC) and/or minimal clinically important 
difference (MCID) are important psychometric properties which need to be evaluated to justify 
clinical use of outcome measures.8 Additionally, tools used to track and measure patient 
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outcomes should be validated in the population in which they are used to be most beneficial. 
Lastly, these tools need to be evaluated in light of clinical utility, including the availability of 
resources, cost, ease of use, and availability of normative data. To date, Oncology EDGE Task 
Forces have reviewed quality of life measures and measures of strength and muscular endurance 
for the prostate cancer population.12,13 These reviews are in addition to 13 reviews completed for 
the breast cancer population,14-26 four reviews completed for the head and neck cancer 
population,27-30 and one review for the colorectal cancer population.31  The purpose of this 
systematic review is to make recommendations of the best methods to evaluate functional 
mobility in PCS based on psychometric properties and clinical utility. 
METHODS 
Search Strategy 
 The authors systematically assessed the literature for outcome measures that either 
directly measured or utilized patient self-report to evaluate functional mobility with the express 
purpose of evaluating the psychometric properties and clinical utility of these measures for 
patients with prostate cancer. The primary literature search took place from February to March 
2014 using electronic databases such as Google Scholar, Ovid, Pubmed/Medline, CINAHL, 
Sports Discus, Web of Science, Cochrane Review, and PEDro. Search terms focused on prostate 
cancer and functional mobility (refer to Appendix A for a full list of search terms).   
  Studies of tests of functional mobility had to report psychometric properties, present 
clinically feasible methods, have adults (preferably male) as participants, and be published in the 
English language to be included in this review. Articles were taken into consideration if 
published after 1995 through March 2014. The authors chose to search from 1995 in order to 
include any seminal research pertinent to the measures investigated.  The prostate cancer 
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population took first priority within the search, however, if no studies included this population, 
patients with other cancers, geriatric patients, other medically complex patients, and the general 
population were considered for review. With the use of such inclusion criteria, we were unable to 
provide evidence on all tests searched, and therefore the list of such tests exceeds the number 
included in the final review. 
 After completion of the literature search, the relevant articles were classified into three 
functional categories consisting of: Walk Tests; Activities of Daily Living (ADL) functional tests 
(physical and self-report); and Self-Reported Community Participation. Each functional category 
included a series of tests and assessments. Refer to Appendix B for measures within each 
category.  
Data Extraction and Analysis 
Each outcome measure was appraised by two reviewers independently using the Cancer EDGE 
Task Force Outcome Measure Rating Form.32 Pertinent information regarding population 
studied, psychometric information related to the measure of interest, and evidence of clinical 
utility was gathered. Assessment of psychometric properties included reliability, where excellent 
reliability = >0.90; good reliability = 0.76-0.89; moderate reliability = 0.50-0.75; and poor 
reliability <0.50.33  Concurrent, discriminative, criterion-related and construct validity values are 
reported when available, as well as measures assessing responsiveness to change such as MDC 
and MCID; the standardized response mean was also reported if that was the only measure of 
responsiveness available. 
Outcome measures were then rated 1–4 (lowest to highest recommendation) on the 
Cancer EDGE Rating Scale, taking into consideration both psychometric qualities and clinical 
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utility (see Figure 1). If the two reviewers agreed on the rating of the outcome measure, the 
rating stood. If an outcome measure rating was found to be in disagreement between the two 
independent reviewers, the disagreement was resolved by discussion with all five reviewers until 
agreement was obtained. Finally, all articles reviewed for an outcome measure were included in 
a reference section of the EDGE form for each appropriate measure.  
RESULTS 
The initial literature search of electronic databases and bibliographic review for functional 
mobility assessments of those treated for prostate cancer resulted in 38,373 articles including 
duplicates. After title and abstract review, and removal of duplicates, 248 articles were retrieved 
and assessed for eligibility. A total of 152 articles met inclusion criteria and were included in the 
final review. Figure 2 delineates the flow of the literature search. 
 Each functional mobility category included multiple tests.  For ten walk tests, 100 articles 
were reviewed. For five activities of daily living functional tests, 22 articles were reviewed.  In 
the Self-Report of Community Participation, 30 articles were reviewed for the seven measures 
assessed. Some research studies included psychometric analysis of multiple measurement tools 
such that the number of articles included within each category is not mutually exclusive.  
Overall, seven measures are highly recommended (rated 4) by the Oncology EDGE Task 
Force. All highly recommended measures are in the walk test category:  2- and 6-Minute Walk 
Tests, 10-meter timed walk, TUG, 5xSTS, SPPB, and the Physical Performance for Patients with 
Cancer (PPB).  Three Activities of Daily Living Tests are recommended (rated 3) by the Task 
Force, and include:  the Assessment of Life Habits (LIFE-H), the Functional Independence 
Measure (FIM), and the Activity Measure for Post-Acute Care (AM-PAC).  Table 1 provides 
summary information regarding recommended measurement tools. 
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Table 2 lists outcome measures not recommended by the EDGE task force with a 
description of weaknesses of the measures.  The Oncology EDGE Task Force is unable to 
recommend (rated 2B) the 12-minute walk test or the Timed 25 Foot Walk in the Walk Test 
category, or the Barthel Index and the Canadian Occupational Performance Measure in the ADL 
Functional Mobility category. No measures in the Self-Reported Community Participation 
Measures achieved a rating of 3 or 4.  The Impact on Participation and Autonomy Questionnaire 
(IPAQ), the Life Satisfaction Questionnaire (LISAT-9), the Modified Rankin Scale and the 
Participation Objective, Participation Subjective (POPS) are rated 2B, unable to recommend, and 
the Participation Survey of Mobility Limited People (PARTS-M), Functional Status Examination 
(FSE), the High Level Mobility Assessment Tool (HiMAT), and the Reintegration to Normal 
Living/Life Index, are all not recommended (rated 1) by the Task Force.  
Table 3 provides details on clinical utility of recommended measures.  A summary of 
psychometric properties for the recommended measures are found in table 4 (reliability and 
responsiveness data) and table 5 (validity data).   
 
DISCUSSION 
 
The purpose of this systematic review is to make recommendations of the best methods to 
evaluate functional mobility in PCS based on psychometric properties and clinical utility. Men 
treated for PC with ADT are known to have reduced lower body strength by 22% and decreased 
bone density compared to healthy controls;5,34-36 combined with increased age, this combination 
sets-up increased risk for falling with functional activities such as rising from a chair, dynamic 
balance activities such as reaching, and slowing gait speed with ambulation.36 It is important to 
assess walking, balance and functional ability in the home and community environments during 
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the initial examination to determine the presence of physical impairments, functional deficits and 
activity limitations, and participation restrictions, in order to identify the impact of cancer 
treatment on the individual’s overall function, including fall risk. 
Within the ICF, functional mobility is included in the mobility domain, and intersects 
with ADLs and participation within environment and life situation contexts. This review includes 
multiple measures of walking, ADLs, and self-reported community function. The seven highly 
recommended (rating of 4) and three recommended (rating of 3) measures are discussed; the 
remaining measures reviewed that lack either psychometric support or clinical utility are not 
recommended for use by the EDGE Task Force. Included highly recommended measures are: 2-
MWT and 6-MWT, the 10-meter timed walk, the (TUG), the 5xSTS, the SPPB, and the PPB. 
Recommended measures include the LIFE-H, the FIM and the AM-PAC. Most of the 
recommended measures, seven, are from the walk test category while three are from the ADL 
category. 
Walk Tests 
The ability to walk safely and competently is essential for an individual to move around 
the environment. The 2MWT and 6MWT involve the individual walking as far as they can in 2 
or 6 minutes respectively. A participant may rest at any time and use a walking aid as needed. 
These tests demonstrated good-excellent reliability in older adults, neurological populations and 
amputees (ICC=0.83-0.96).37-39 The reliability of the 6MWT was examined in a mixed cancer 
cohort and is excellent with an ICC = 0.93.40 Discriminant validity was established with 
community dwelling adults and those in long term care.37 The 2MWT has moderate to high 
concurrent validity with the TUG, as well as other walk tests such as the 6- and 12-MWT, and 
the 10-meter timed walk.37,39,41,42 There is moderate concurrent validity of the 6-MWT with 
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SPPB and 5xSTS;42 it also demonstrates moderate concurrent validity with the physical function 
subscale (r=0.50) of the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36),43 
and the perceived physical function (r=0.55) on the European Organisation for Research and 
Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-30).40 Both the 2- and 6-
MWT are easy to administer clinically and their common clinical use and available normative 
data37,44,45 allows for rapid interpretation by the clinician. The established MDC95 for the 6-MWT 
is 5.2%,46 and the MCID of 140 feet is reported for PCS.47 The 2-MWT may have a slight edge 
in terms of clinical utility as it takes less time to administer, may be more feasible for those with 
significant levels of fatigue or muscle weakness, or a gait dysfunction which results in greater 
energy consumption.48  Both the 2-MWT49 and the 6-MWT40,47,50 have been used to assess 
outcomes in research studies involving PCS. 
The 10-meter timed walk test is also highly recommended for use by the Oncology 
EDGE Task Force. This test measures the time it takes to walk the distance of 10 meters. Gait 
speed is calculated as the time it took to complete the test is divided by the distance. The 10-
meter walk test has been used in studies among men with prostate cancer, and demonstrates 
excellent reliability (ICC=0.90-0.97).51-60 Furthermore, this test was validated with dependence 
in self-care, domestic life, and mobility, with IADLs, the Barthel Index, the 6-MWT and the 
TUG.57,61,62 The responsiveness of the 10-meter timed walk has been investigated and the MDC 
is 0.013-0.25m/s. 52,53,61,63 The ease of administration of this test and available normative 
data56,59,64,65 makes it a good test to utilize clinically. 
Another highly recommended test is the Timed Up and Go. This test involves an 
individual rising from sitting in a standard armchair, walking for 3 meters, then turning and 
walking back to the chair and sitting down.66 The time to complete this test is recorded. The 
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TUG has moderate to excellent reliability, ICC=0.85-0.96.38,46,67 Concurrent validity was 
established with 2-MWT and FIM.68 In the cancer population, the time on the TUG predicts falls 
within 3-12 months of diagnosis.67 Normative data is available for the TUG for community 
dwelling elders as well as for PCS.47,69-72  In addition to psychometric data related to PCS, the 
TUG has been used as an outcome measure in research with men treated for PC.47,73 
The 5xSTS is also highly recommended. This test involves rising from a standard chair 5 
times as fast as possible, with arms folded across the chest, and is focused on transitional 
movements and lower extremity strength.74 The time to complete the test is recorded in seconds. 
This test is easy to administer in the clinic and is reliable in older female adults (ICC=0.95).75 
The 5xSTS was validated with the 6-MWT42 and the TUG.75  The MDC in older female adults is 
2.5 seconds.75 Additionally, this test was used in research on the prostate cancer 
population.50,76,77 This test incorporates assessment of both transitional movement and a 
functional measure of lower extremity strength making this a useful clinical tool. 
Two functional performance batteries, the Short Performance Physical Battery (SPPB), 
and the Physical Performance Battery for Patients with Cancer (PPB), are highly recommended 
by the EDGE Task Force.  The SPPB is a collection of physical tests that determine function in 
activities of daily living. The SPPB is easy to administer and involves walking at a normal pace, 
a balance task, and incorporates the 5xSTS.78  The design of the test makes it relatively easy to 
administer in a clinical setting, and seeks to quantify physical performance on a number of 
simple skills required for functional mobility.78 Reliability is good (ICC=0.83-0.89)79-82 and it is 
validated with self-reported mobility and ADL with associated disability.78 The MDC in the 
elderly population is 1.42 – 2.9 points83,84 and in a population of older adults status post hip 
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fracture, the MDC is 3.42 points.85 This test was utilized in research with individuals with 
advanced cancer, including prostate cancer.86   
The PPB was specifically designed for the oncology population, and has been used in 
research with men treated for prostate cancer.87 The PPB includes nine tests, and although it may 
take up to 40 minutes to complete, the test demonstrated moderate to excellent reliability, 
ICC=0.69-0.99, in a general cancer population.88 Concurrent validity of the separate sub-tests 
(walk, sit-to-stand, 6-MWT) was established with the TUG 67  and with the Functional Status 
Index.88   The PPB was designed for use with those with cancer and includes a comprehensive 
evaluation of physical performance making this a promising test to incorporate into clinical 
measurement. 
The remaining walk tests, including the 12-MWT and the Timed 25 Foot Walk are both 
rated 2B, unable to recommend, by the EDGE Task Force.  Both of these tests have lower 
psychometric strength or lack adequate testing of psychometric qualities.  The 12-MWT may be 
difficult to administer in an individual with a lower level of function secondary to the duration of 
the test, and the Timed 25 Foot Walk has only been tested with a neurological population, 
making generalization to men treated for prostate cancer difficult. 
Activity of Daily Living Functional Tests 
Three ADL functional tests are given a rating of 3, recommended, the highest rating 
given by the EDGE Task Force in this category. They are the LIFE-H, the FIM, and the AM-
PAC. The LIFE-H has a long and short form, covering 12 domains, with the number of items 
being 240 and 69 respectively.89-93 The domains include: personal care, interpersonal 
relationships, nutrition, community life, recreation and mobility, with the intent to assess the 
perception of one’s ability to participate socially.  The scoring is complex and the time to 
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administer the test (one hour for the short form and two hours for the long form) may impact its 
clinical utility. However, sound psychometric properties and the comprehensive nature of the test 
warrant the investment of time. The validity of the LIFE- H has not been reported in a cancer 
population. 
The FIM contains 18 items comprised of 5 cognitive and 13 motor tasks. The FIM is used 
to assess quality of life in persons with a disability and the need for assistance to complete 
activities within the individual’s environment.94 The FIM has good psychometric properties,95-98 
however the FIM’s clinical utility may be restrictive as the FIM has a cost associated with use, 
takes 30 - 40 minutes to administer, and is scored via consensus with other health care providers. 
Also, therapists need to be trained to utilize the tool. Despite these barriers to implementation, 
the EDGE Task Force recommends this tool because of the comprehensive nature of the 
assessment, which provides the clinician with a clear picture of the impact of function on quality 
of life and daily activity. Use of the FIM has not been reported in the prostate cancer population. 
The AM-PAC was developed to assess functional status of all individuals across the 
continuum of care.99  Based on ICF domains, the AM-PAC is a self-report 41-item 
comprehensive scale to test physical and movement activity (10 items), personal care and 
instrumental activity (16 items), and applied cognitive activity (15 items).  The test-retest 
reliability is excellent (ICC=0.91-0.97),99-101 and validation with proxy scoring is moderate-good 
(ICC=0.68-0.90).100  Furthermore, shortened computer assisted testing versions are available that 
demonstrate excellent concurrent validity with the full version (r>0.90).101-103 Although a broad 
population was recruited to examine the psychometric properties of this tool, this measure has 
not been specifically reported in the cancer population. 
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The Task Force is unable to recommend the remaining ADL measures including the 
Barthel Index and the Canadian Occupation Performance Measure because of limited 
psychometric support and lack of evidence of use in a cancer population. 
Self-Reported Community Participation Measures 
No measures in this category are recommended due to poor psychometric properties, 
poor clinical utility, and lack of evidence of use in a cancer population. The IPAQ, the LISAT-9 
Modified Rankin Scale, and the POPS are all rated 2B. The PARTS-M, HiMAT, FSE, and 
Reintegration to Normal Living/Life Index are all not recommended by the Task Force. 
Limitations and Future Research 
Evidence based practice requires that the best evidence available is utilized in clinical 
judgement, along with clinician expertise and patient values.  The EDGE Task Force 
investigating measures of functional mobility for use with PCS acknowledges limitations to this 
study.  The literature search was completed in March of 2014, and therefore does not include any 
studies published thereafter which might color the lens through which the analysis of findings is 
viewed.  It is possible that newer studies would provide additional psychometric data to evaluate 
existing measures, or that new measures may have been developed.  Limiting the search to 
English publications could also limit the access to evidence supporting particular measures.  The 
Task Force recommendations are made with the best available evidence at the time, but in using 
these measures, the reader is encouraged to continue to use best judgement in applying these 
recommendations to the individual patient. 
Clearly, additional research is needed in validating all of these measures in the prostate 
cancer population.  Studies examining reliability and responsiveness to change of these measures 
in men treated for prostate cancer is a significant gap in the evidence database.  More studies 
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utilizing these measure as outcomes need to be developed.  Perhaps most importantly, better 
measures of assessing functional mobility within the context of community participation need to 
be developed.   
Conclusion 
In patients with prostate cancer, with or without ADT, the assessment of functional 
mobility is important to assess impairment, functional deficits, activity limitations, and 
participation restrictions. Multiple assessment tools exist to assess walking and ADLs, however, 
limited research in Self-Reported Community Participation tools render them inadequate at this 
time. Seven tests are highly recommended by the Oncology EDGE Task Force; 2- and 6-MWT, 
10-meter timed walk, the TUG, the 5xSTS, the SPPB, and the PPB, based on good clinical utility 
and psychometric properties. Three tests are recommended but lack use in the cancer population:  
LIFE-H, the FIM, and AM-PAC.  Further research is needed to establish psychometric properties 
of other current measures including validation among PCS, or to develop new assessment tools 
in the prostate cancer population.  
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 Table 1:  Summary of Recommended Outcome Measures 
Measure 
Prostate 
Cancer 
EDGE Task 
Force Rating 
Features 
2-Minute Walk (2-MWT) 4 
Quick and easy administer, no training required, used in 
PCS 
6-Minute Walk (6-MWT) 4 
Free, easy to administer, no training required, evidence 
cancer populations and used in PCS 
10-Meter Timed Walk 
(10-MTW) 
4 
Free and easy to administer, measures gait speed, not 
used in PCS 
Timed-Up and Go (TUG) 4 
Performance-based, predicts falls, commonly used in 
clinical setting. Evidence with PCS 
5 times sit-to-stand 
(5xSTS) 
4 
Quick and easy to administer, no training required, 
assesses functional mobility and strength, not used in 
PCS 
Short Performance 
Physical Battery (SPPB) 
4 Easy to administer, measures function of ADLs. 
Physical Performance 
Battery for Patients with 
Cancer (PPB) 
4 
Specific to the cancer population. Comprehensive 
physical performance assessment. 
Assessment of Life 
Habits (LIFE-H) 
3 
Takes time to complete and is difficult to score. Low 
clinical utility 
Functional Independence 
Measure (FIM) 
3 
Cost to purchase. 30-40 minutes to complete. Not used 
in cancer population but has good psychometric 
properties 
Activity Measure for Post-
Acute Care (AM-PAC) 
3 
Based on ICF domains; has computer assisted testing 
short versions. 
Abbreviations: PCS survivors of prostate cancer; ADLs activities of daily living
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Table 2:  Summary of Outcome Measures NOT Recommended 
 
Measure 
Prostate 
Cancer 
EDGE Task 
Force 
Rating 
Features 
12-Minute Walk Test 2B 
Lower psychometrics; may be difficult to administer to 
lower functioning individuals.  Used with/validated in a 
primarily neurological population. 
Timed 25 Foot Walk 2B 
Lacks comprehensive psychometric testing and only 
tested with multiple sclerosis. 
Barthel Index 2B 
Only adequate internal consistency.  Validated in primarily 
geriatric and Parkinson’s populations. 
Canadian Occupational 
Performance Measure 
2B 
Fee to use, used by occupational therapists more than 
physical therapists. Validated only in a neurological 
population. 
Impact on Participation 
and Autonomy 
Questionnaire (IPAQ) 
2B 
30 minutes to complete, focuses on autonomy and 
participation. Limited psychometrics. Primarily used with 
the neurologically impaired. 
Life Satisfaction 
Questionnaire (LISAT-9) 
2B 
10 - 30 minutes to complete, developed for SCI and used 
with other neurological pathology such as CVA, TBI, MS. 
Modified Rankin Scale 2B 
Developed for CVA, 6-30 minutes to complete, 
experience raters needed to decrease bias. 
Participation Objective, 
Participation Subjective 
(POPS) 
2B 
Poor psychometrics in traumatic brain injury. 6- 30 
minutes to complete.  
Participation Survey of 
Mobility Limited People 
(PARTS-M) 
1 
20 - 40 minutes to complete online or 60 - 90 minutes 
hard copy.  Used with a neurologically impaired 
population such as cerebral palsy, movement disorders, 
MS, SCI. 
Hi-Level Mobility 
Assessment Tool 
1 Developed specifically for high level traumatic brain injury 
Functional Status 
Examination 
1 
Assesses ADL function and cover ICF but lengthy to 
administer; only used in traumatic brain injury 
Reintegration to Normal 
Living/Life Index 
1 
Covers multiple domains for normal social interaction; 
lacks robust psychometrics. 
Abbreviations:  CVA cerebral vascular accident; TBI traumatic brain injury; MS multiple 
sclerosis, ICF International Classification of Functioning and Health.  
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 Table 3:  Clinical Usefulness of Recommended Measures 
Measure Equipment Needed Cost Ease of Use 
Scoring/ 
Interpretation 
Normative 
Data 
Two-Minute Walk Yes – Stopwatch Free High Easy Yes 
Six-Minute Walk Yes – Stopwatch Free High Easy Yes 
Ten-Meter Timed 
Walk 
Yes - Stopwatch Free Medium – varied 
procedures 
Easy Yes 
Timed-Up & Go Yes – Stopwatch, 
chair, measuring tape 
Free High Easy Yes 
Five Times Sit-to-
Stand 
Yes – Stopwatch, 
standard chair 
Free High Easy Yes 
Short 
Performance 
Physical Battery 
Yes – Stopwatch, 
chair, measuring 
tape, cones 
Free High Easy Yes 
Physical Battery 
for Patients with 
Cancer 
No Free High Difficult Yes  
Assessment of 
Life Habits 
No Minimal High Difficult Yes 
Functional 
Independence 
Measure 
Yes – varies based 
on category  
Moderate Low – Training 
Required 
Moderate Yes 
Activity Measure 
for Post-Acute 
Care 
No Minimal Medium Moderate Yes 
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Table 4:  Psychometric Properties of Recommended Measures Related to Reliability and Responsiveness 
Test Test-Retest Reliability 
Intra-rater 
Reliability 
Inter-rater Reliability 
Sensitivity to Change 
MDC/MCID 
Walk Tests 
Two-Minute 
Walk Test (2-
MWT) 
(distance in 
meters) 
Older Adults:37 ICC=0.94-0.95 
 
CVA:38 ICC=0.98 (0.97-0.99) 
Neurological Population:39 
ICC=097 
 
Amputee:46 ICC=0.83 (0.71-0.90) 
Older Adults:37 
ICC=0.94-0.96 
 
CVA104 ICC=0.85 
Older Adults:37 
ICC=0.94-0.96 
 
CVA:104 
ICC=0.85 
Older Adults:37 MDC90=12.2-14.7 
 
CVA:38 MDC95=13.4 (23%) 
 
Amputee:46 MDC90=34.3 
Six-Minute Walk 
Test (6-MWT) 
(distance in 
meters) 
Amputee:46 ICC=0.97 (0.95-0.99) 
 
Cancer population:40 ICC=0.93 
 
Healthy:105 r =0.90 
CVA:104 ICC=0.78 CVA:104 ICC=0.74 Amputee:46 MDC90=4%, MDC95=5.2% 
 
Prostate Cancer:47 MCID=140 feet 
10-Meter Timed 
Walk (10-MTW) 
(time in seconds) 
Healthy Older Adults:106 
ICC=0.98 (0.96-0.99) 
 
Neurological Population:39 
ICC=0.93 
  Healthy Older Adults:106 MDC90/95 
=0.01m/s 
 
Older Adults:83  
MCID=.05m/s 
Substantial change=0.1m/s 
Timed-Up & Go 
Test(s) (TUG(s)) 
(time in seconds) 
CVA:38 ICC=0.97 (0.94-0.99) 
 
Amputee:46 
ICC=0.88 (0.80-0.94) 
 
Cancer Population:67 
TUG with Walk Subtest on PPB: 
r=0.85 
TUG with Sit stand subtest on PPB:  
r=0.75 
TUG with 6MW subtest on PBB: 
r=-0.62 
  CVA:38 MDC95=7.84 
 
Amputee:46 MDC90=3.6 seconds 
 
Cancer Pop – Falls within 3-12 mos:67 
ROC=0.85 
Cancer Pop – Falls since Ca Dx:67  
ROC=0.74 
 
Prostate Cancer:47 
MCID= 1s 
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Five Times Sit-to-
Stand Test 
(5xSTS) 
(time in seconds) 
Older female adults:75 
ICC=0.95 
  Older Female Adults:75 
MDC95=2.5(17.5%) 
Short Physical 
Performance 
Battery (SPPB) 
ICC=0.83-0.89   Older Adults83 
MCID=0.5 points, Substantial change= 1 
Physical 
Performance 
Battery for 
Cancer (PBB) 
Ca general:88 ICC=0.69-0.99  Ca general:88 ICC=0.98-
0.99 
Walk subtest Falls within 3-12 mos:67 
ROC=0.60-0.69 
Since Ca Dx:67 ROC=0.55 
 
Sit-stand Subtest Fall within 3-12 mos:67 
ROC=0.72-0.80 
Since Ca Dx:67 ROC=0.61 
 
6-MWT subtest Fall within 3-12 mos:67 
ROC=0.29-0.35 
Since Ca Dx:67 ROC=0.30 
ADL Functional Tests 
Assessment of 
Life Habits 
Neurological Population 
Long form:89,93 ICC=0.74-0.89 
Short Form:93 ICC=0.83 
 
Older Adults:91,92 ICC≥0.84 
 Neurological 
Population:93,107 
ICC=0.89 
Neurological Population:90 
MCID=0.5 points  
Functional 
Independence 
Measure (FIM) 
Elderly Adults 
Motor:  ICC=0.9096 
Cognitive:  ICC= 0.8097 
 
Neurological Population:107 
Total scale   r=0.90 
 Across Populations:108 
ICC= 0.124-0.661 
Effect Size (neurological population):109 
Motor: Cohen’s d =1.24 
Cognitive: Cohen’s d= 1.05 
Activity Measure 
for Post-Acute 
Care (AM-PAC) 
Mixed post-acute dx:100 
Daily activity:  ICC=0.96 
Mobility:  ICC=0.97 
Applied Cognition:  ICC=0.91 
 Mixed post-acute dx:100 
Daily activity:  ICC=0.90 
Mobility:  ICC=0.86 
MDC95 (points):110 
Daily activity:  3.7 
Mobility:  4.28 
Applied Cognition:  5.55 
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Applied Cognition:  
ICC=0.68 
 
MCID (late stage lung ca):111 
AM-PAC CAT = 2 points 
 
Orthopedic/neurological/complex 
medical populations:10 
SRM = -0.02-0.10 
Abbreviations:  Ca = cancer; CAT = computer assisted testing; CVA = cerebrovascular accident; dx = diagnosis; ICC = interclass correlation 
coefficient; MDC = minimal detectable change; MCID = minimal clinically important difference; mos. = months; r = Pearson’s correlation 
coefficient; ROC = receiver operating characteristic curve; SRM = standardized response mean 
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Table 5:  Psychometric Properties of Recommended Measures Related Validity 
 Criterion Validity Construct Validity 
Test Concurrent Validity Predictive Validity  Convergent Discriminant 
Walk Tests     
Two-Minute Walk 
Test  
(2-MWT) 
 
TUG: r=-0.8737, r=-0.68 to -0.8141 
Berg Balance37: r=0.88 
6-MWT: r=0.9337, r=0.99104 
t-test p=0.8245 
12-MWT:04 r=0.99 
10-Meter Timed Walk:39 ICC= -0.61 
FIM:41: r=0.47-0.59 
Neurological Population39 
Between those with/ without 
assistive device p<0.001 
Between those with/ without 
sensory loss p=0.022 
 CI95 for mean between 
group difference among 
long term care and 
community dwelling 
older adults:37  
(44.2, 101.6)  
 
Six-Minute Walk 
Test  
(6-MWT) 
2-MWT:104 r=0.99 
12-MWT: 104 r=0.99 
Short Physical Perf Battery:42 r=0.61 
5xSTS:42 r=-0.62 
With VO2peak:40 r=0.67 
With Wmax:40 r=0.70 
With Perceived Phys Function 
(ERTOC QQ-C30 Physical 
Function):40 r=0.55 
With SF-36:43 r=0.50 
 Pre- to post-operative 
abdominal surgery:43 SRM 
= 0.70 
 
Post-operative two time 
points:43  
SRM = 0.54 
Pre- to Post-operative 
abdominal surgery:43 
r=0.75-0.87 
10-Meter Timed 
Walk 
Neurological Population39 
2-MWT: ICC=-0.61 
   
Timed-Up & Go 
(TUG) 
2-MWT:41 r=-0.68 to -0.81 
FIM:41 r=-0.42 to -0.59 
   
Five Times Sit-to-
Stand Test (5xSTS) 
6-MWT:42 r=0.61 
TUG:75 r=0.64 
Functional reach:75 r=0.36 
   
Short Physical 
Performance 
Battery (SPPB) 
6-MWT:42 r=0.61    
Physical 
Performance 
Walk Subtest with TUG:67 r=0.85 
STS subtest with TUG:67 r=0.75 
   
39 
 
Battery for Cancer 
(PBB) 
6-MWT subtest with TUG:67 r=-0.62 
With Functional Status Index88  
Overall: r=0.25-0.51 
personal care: r=0.11-0.53 
mobility: r=0.15-0.44 
ADL Functional Tests 
Assessment of Life 
Habits (LIFE-H) 
With CHART physical 
independence):93 r=0.76 
With CIQ:93 r=0.54-0.75 
 Long Form Internal 
Consistency:93 
Cronbach’s α=0.90 
Short Form Internal 
Consistency:93 
Cronbach’s α=0.82 
 
Functional 
Independence 
Measure (FIM) 
SCI with Barthel Index:98  
r =0.92-0.94 
Minutes of Assistance:112 
83% 
Supervision:112 
82% 
 
Internal consistency - SCI98 
Total: Cronbach’s α=0.91-
0.92 
Motor: Cronbach’s 
α=0.91-0.92 
Cognitive: Cronbach’s 
α=0.90. 
 
Internal consistency – 
Neuro population109  
Total: Cronbach’s α=0.98 
Motor: Cronbach’s α=0.97 
Cognitive: Cronbach’s 
α=0.96 
 
Assessment of Life 
Habits (AM-PAC) 
 Point score decline associated 
with symptom worsening and 
adverse events in lung 
cancer:111 
2 point decline: OR = 1.12-
1.38 
5 point decline: OR = 1.18-
1.77 
Internal consistency – 
mixed populations:99 
Cronbach’s α = 0.92-0.94 
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10 point decline: OR = 0.99-
2.15 
 
New/progressive brain 
metastasis:111 
2 point decline: OR = 1.28 
5 point decline: OR = 1.77 
10 point decline: OR = 2.15 
 
Abbreviations:  α = alpha; CHART = Craig Handicap Assessment and Reporting Technique; CIQ=Community Integration Questionnaire; OR = odds 
ratio; r = Pearson’s correlation coefficient; SCI = spinal cord injury; SRM = standardized response mean 
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Figure 1: Cancer Task Force EDGE Rating Scale 
 
4 Highly Recommend 
The outcome has good psychometric properties and good clinical 
utility; the measure has been used in research on individuals with 
or post cancer. 
3 Recommend 
The outcome measure has good psychometric properties and 
good clinical utility; no published evidence that the measure has 
been applied to research on individuals with or post cancer. 
 
2A 
Unable to 
Recommend at this 
time 
There is insufficient information to support a recommendation of 
this outcome measure; the measure has been used in research on 
individuals with or post cancer. 
 
2B 
Unable to 
Recommend at this 
time 
There is insufficient information to support a recommendation of 
this outcome measure; no published evidence that the measure 
has been applied to research on individuals with or post cancer. 
1 Do not Recommend 
Poor psychometrics &/or poor clinical utility (time, equipment, 
cost, etc.) 
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Figure 2. Flow of literature search. 
 
  
Data Bases Searched: 
Academic Search Premier, Medline, CINAHL, 
PubMed, PEDro, Sports Discus, Google Scholar, 
OVID, Cochrane Database of Systematic Reviews 
Articles found: 38373 
Records after duplicates removed: 
352 
Articles screened for 
eligibility: 248 
Articles 
excluded from 
title and 
abstract review: 
104 
Full-text articles included 
in synthesis: 152 
Walk tests: 
100 
Self-report: 
30 
Activities of Daily Living:  
22 
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Appendix A 
Primary search terms: prostate cancer, neoplasm, function, mobility, functional mobility, 
activities of daily living, and walking. 
Secondary search terms: 
 Five Times Sit to Stand (5xSTS) 
 10-Meter Timed Walk 
 Two-Minute Walk Test (2-MWT) 
 Six-Minute Walk Test (6-MWT) 
 12-Minute Walk Test (12-MWT) 
 Activity Measure for Post-Acute Care (AM-PAC) 
 Assessment of Life Habits (LIFE-H) 
 Barthel Index 
 Canadian Occupational Performance Measure (COPM) 
 Clinical Test of Sensory Interaction and Balance (CTSIB) 
 Community Balance and Mobility Scale 
 Functional Independence Measure (FIM) 
 Functional Reach Test/Modified Functional Reach Test 
 Functional Self-Assessment 
 Functional Status Examination (FSE) 
 Goal Attainment Scale 
 Hauser Ambulation Index 
 High Level Mobility Assessment Tool (HiMAT) 
 Impact of Participation and Autonomy Questionnaire (IPAQ) 
 Life Satisfaction Questionnaire (LISAT 9) 
 Modified Rankin Scale 
 Motor Activity Log 
 Motricity Index 
 Participation Objective, Participation Subjective (POPS) 
 Participation Survey of Mobility Limited People (PSM) 
 Physical Performance Battery for Patients with Cancer (PPB for Ca) 
 Reintegration to Normal Living/Life Index 
 Short Performance Physical Battery (SPPB) 
 Timed 25 Foot Walk 
 Timed Up and Go (cognitive and manual) (TUG) 
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Appendix B:  Categories of Functional Mobility Testing and Respective Tests 
Walk Test Category 
ADL Functional Tests 
Category (Physical and self-
report) 
Self-Report Community 
Participation Category 
 Two Minute Walk Test (2-
MWT) 
 Six Minute Walk Test  
 (6-MWT) 
 12-Minute Walk Test (12-
MWT) 
 10-Meter Timed Walk (10-
MTW) 
 5 Times Sit-to-Stand 
(5xSTS) 
 Timed 25 Foot Walk 
 Timed Up & Go 
(Cognitive and Manual) 
(TUG) 
 High-Level Mobility 
Assessment Tool (HiMAT) 
 Short Performance 
Physical Battery (SPPB) 
 Physical Performance 
Battery for Patients with 
Cancer (PPB) 
 Assessment of Life Habits 
(LIFE-H) 
 Activity Measure for Post-
Acute Care (AM-PAC) 
 Canadian Occupational 
Performance Measure 
(COPM) 
 Barthel Index 
 Functional Independence 
Measure (FIM) 
 Functional Self-Assessment 
 Impact on Participation 
and Autonomy 
Questionnaire (IPAQ) 
 Life Satisfaction 
Questionnaire (LISAT-9) 
 Functional Status 
Examination (FSE) 
 Modified Rankin Scale 
 Participation Objective, 
Participation Subjective 
(POPS) 
 Participation Survey of 
Mobility Limited People 
(PARTS-M) 
 Reintegration to Normal 
Living/Life Index 
 
 
 
 
